Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Heinzer

Showing results (71-80 of 145) with videos related to

Pageof 15
Sort By:
Journal of Endourology|March 22, 2008
Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sumPierre I Karakiewicz, Felix K-H Chun, Andrea Gallina, et al.
European Urology Focus|May 27, 2018
Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results databaseFelix Preisser, Marco Bandini, Elio Mazzone, et al.
The Journal of Urology|September 9, 2014
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomyUwe Michl, Frederike Molfenter, Markus Graefen, et al.
Molecular Oncology|August 15, 2013
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancersKatharina Grupp, Stella Sanader, Hüseyin Sirma, et al.
International Journal of Cancer|October 12, 2020
Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancerKatharina Möller, Martina Kluth, Malik Ahmed, et al.
BMC Cancer|July 24, 2015
The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionChristoph Burdelski, Devi Menan, Maria Christina Tsourlakis, et al.
Urologic Oncology|May 4, 2019
Prostate cancer prognosis in men with other malignancies prior to radical prostatectomyPeter Klippenstein, Thorsten Schlomm, Gunhild von Amsberg, et al.
The Journal of Urology|February 13, 2014
A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomyMeike Adam, Amir Hannah, Lars Budäus, et al.
Human Pathology|February 22, 2015
Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancersChristoph Burdelski, Ysé Barreau, Ronald Simon, et al.
Urology|August 12, 2008
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancerUmberto Capitanio, Sasha Ahyai, Markus Graefen, et al.
Pageof 15

Showing results (71-80 of 145) with videos related to

Sort By:
Pageof 15
Journal of Endourology|March 22, 2008
Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sumPierre I Karakiewicz, Felix K-H Chun, Andrea Gallina, et al.
European Urology Focus|May 27, 2018
Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results databaseFelix Preisser, Marco Bandini, Elio Mazzone, et al.
The Journal of Urology|September 9, 2014
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomyUwe Michl, Frederike Molfenter, Markus Graefen, et al.
Molecular Oncology|August 15, 2013
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancersKatharina Grupp, Stella Sanader, Hüseyin Sirma, et al.
International Journal of Cancer|October 12, 2020
Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancerKatharina Möller, Martina Kluth, Malik Ahmed, et al.
BMC Cancer|July 24, 2015
The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionChristoph Burdelski, Devi Menan, Maria Christina Tsourlakis, et al.
Urologic Oncology|May 4, 2019
Prostate cancer prognosis in men with other malignancies prior to radical prostatectomyPeter Klippenstein, Thorsten Schlomm, Gunhild von Amsberg, et al.
The Journal of Urology|February 13, 2014
A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomyMeike Adam, Amir Hannah, Lars Budäus, et al.
Human Pathology|February 22, 2015
Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancersChristoph Burdelski, Ysé Barreau, Ronald Simon, et al.
Urology|August 12, 2008
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancerUmberto Capitanio, Sasha Ahyai, Markus Graefen, et al.
Pageof 15